A New Line Of Sight
Into Targeted Cancer Therapies

Our team is comprised of leading industry experts with deep radiotherapy development experience

Frances L. Johnson, MD
Co-Founder, Chief Executive Officer

Frances L. Johnson, MD is a physician scientist and entrepreneur with experience leading multi-disciplinary teams in academic, government and private enterprise settings. Dr. Johnson received a BS in Cell and Molecular Biology and a Doctorate in Medicine from the University of Washington followed by Internal Medicine residency at the University of California San Francisco and Cardiovascular Medicine fellowship at Stanford University. Her experience includes co-founding a biomedical startup (XDx; now CareDx, NASDAQ:CDNA) as a co-inventor of their molecular diagnostic technology while on Stanford’s faculty. Dr. Johnson remained in academics during the growth phase of CareDx and led heart transplant teams at three academic medical centers before co-founding Viewpoint Molecular Targeting with Dr. Schultz and Mr. Coleman. As CEO at Viewpoint, Dr. Johnson has successfully secured multiple competitive Phase I and Phase II National Institutes of Health/National Cancer Institute funded Small Business Innovation Research Grants and Contract Projects ($10M). Dr. Johnson has successfully developed a team that has secured the first of two IND approvals expected in 2021 to begin the clinical trials of Viewpoint radiopharmaceuticals.

 

Michael K. Schultz, PhD
Co-Founder, Chief Science Officer

Michael K. Schultz, PhD is the principal inventor of Viewpoint’s radiopharmaceuticals and directs ongoing development programs. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has maintained continuous research funding for his laboratory for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters, and invited publications. Dr. Schultz (as Co-Principal Investigator) was awarded a competitive NIH Research Project Grant (R01) to perform the non-clinical research and development needed to advance Viewpoint’s alpha-particle therapy for neuroendocrine tumors to a Phase 1 clinical imaging and therapy trial to be conducted at the University of Iowa. Dr. Schultz is Principal Investigator or Co-Investigator (with CEO and CMO Frances Johnson, MD of Viewpoint) on over $10M of NCI funded Small Business Innovation Research grant projects. In addition to his role on the current R01 ($3.5M), Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors (a $10M, 5-year grant) and has been the primary architect, Principal Investigator, or Co-Investigator on over $20M in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security, and industry funded research projects. Dr. Schultz has five years of experience in product management in radiation detectors, electronics, and software (PerkinElmer/Ametec) and 17 years of experience in radiopharmaceutical CMC/IND approvals, including as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States.

Ewa Matczak, MD
Chief Medical Officer

Dr. Matczak is a medical oncologist/hematologist who spent the first 10 years of her career in basic science research, clinical research and teaching. Her post-medical training included fellowships and research positions at the National Cancer Institute, Columbia Presbyterian Medical Center and Harvard Medical School. She then transitioned to industry and has over 20 years of experience in early and late-stage drug development, particularly in solid tumors and hematology/oncology. Dr. Matczak has held clinical development roles at multiple leading global pharmaceutical companies including, Bayer, Novartis, Eisai and Pfizer.

Dr. Matczak most recently served as VP, Clinical Sciences at Glenmark Pharmaceuticals, where she was responsible for leading development with focus on immune-oncology and building the oncology team. Prior to that, she served as the Associate VP, Oncology at Hengrui Therapeutics where she played a key role in development, oversight and establishment of the company’s Oncology program. For nearly a decade she held roles at Pfizer, including Director and Senior Director of Global Medical Affairs as U.S. Sutent Lead and RCC Lead; and Bosutinib Global Clinical Lead in Clinical Development. During her time at Pfizer, she provided leadership in commercial and drug development strategies, clinical trial design, Investigator-initiated research strategies and implementation. Additionally, Dr. Matczak served as Senior Director /International Program Team Leader at Eisai Pharmaceuticals for two targeted therapy agents in early development; Medical Director/Clinical Investigations Leader in the Research & Development Oncology Business Unit, Novartis Pharmaceutical Corporation; and Associate Medical Director/Medical Expert for Clinical Pharmacology at Bayer HealthCare Pharmaceutical. Prior to industry she spent over a decade in basic science research, clinical research and teaching at Columbia Presbyterian Medical Center, the US NIH National Cancer Institute, and Harvard Medical School.

Dr. Matczak received her Medical Degree from SUNY Downstate, NY. She completed her internal medicine internship, and residency and oncology/hematology fellowship at Columbia Presbyterian under Dr. Karen Antman in New York and she completed her HIV Oncology training and research at Harvard Institute of Medicine/Beth Israel Deaconess with Jerome Groopman where she remained on faculty until she joined the Clinical Trial Evaluation Program (CTEP) at the National Cancer Institute (NCI). She was a National Institute of Health (NIH) Intramural Research Awardee in Dr. Bob Gallo’s Lab. Dr. Matczak organized and led multi-disciplinary translational research clinics in Kaposi’s Sarcoma and HPV. She was a NIH investigator, and an AIDS Malignancy Consortium and Eastern Cooperative Oncology Group member.

Amos Hedt
Chief Business Strategy Officer

 Mr. Hedt is an experienced research professional with over 20 years in the biotechnology and pharmaceutical industries and a comprehensive understanding of all stages of drug research, development, and product innovation. He has extensive experience and knowledge managing clinical projects with a concentration in early-stage drug development specializing in theranostics, radiopharmaceuticals, mAbs, and vaccines. 

 Mr. Hedt joins the Viewpoint team having most recently served as the Founder and Principal Consultant at Cedalion, a strategic consulting and contract research practice specializing in the biotechnology, pharmaceutical, and diagnostic industries, working to provide strategic development plans, analysis of database and literature, and insight into the competitive landscape for an optimized approach to novel developments. Prior to that, he served as Head of Clinical Development and Strategy for Clarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company developing theranostics for the diagnosis and therapy of cancer, where he played a vital role in the design and implementation of clinical trial programs that drove research and development strategies and advancements. Additionally, Mr. Hedt served as Senior Director, Clinical Operations for Patrys Ltd., a clinical-stage biotechnology company focused on the development of an entirely new type of product for the treatment of cancer – natural human antibodies. He also held a variety of roles at CSL Ltd., an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent severe human medical conditions. 

Mr. Hedt received his Bachelor of Arts in Psychophysiology and Psychology from the Swinburne University of Technology and completed his Graduate and Postgraduate training in the History and Philosophy of Science at the University of Melbourne.